Immunogenicity and reactogenicity of homologous mRNA-based and vector-based SARS-CoV-2 vaccine regimens in patients receiving maintenance dialysis

Faculty of Medicine

Assiut University

Immunogenicity and reactogenicity of homologous mRNA-based and vector-based SARS-CoV-2 vaccine regimens in patients receiving maintenance dialysis

Research Authors
Hristos Karakizlis, Christian Nahrgang, Kevin Strecker, Jiangping Chen, Mostafa Aly, Heiko Slanina, Christian G Schüttler, Isla Esso, Martin Wolter, Darina Todorova, Sönke Jessen, Andrea Adamik, Claudio Ronco, Werner Seeger, Rolf Weimer, Martina Sester, H
Research Date
Research Department
Internal Medicine
Research Journal
Clinical Immunology
Research Member
Mostafa Gaafar Osman Aly
Research Publisher
Academic Press
Research Year
2022
Research_Pages
108961
Research Abstract

Patients receiving maintenance dialysis (MD) are vulnerable to COVID-19-related morbidity and mortality. Currently, data on SARS-CoV-2-specific cellular and humoral immunity post-vaccination in this population are scarce.

We conducted a prospective single-center study exploring the specific cellular (interferon-γ and interleukin-2 ELISpot assays) and humoral immune responses (dot plot array and chemiluminescent microparticle immunoassay [CMIA]) at 4 weeks and 6 weeks following a single dose or a complete homologous dual dose SARS-CoV-2 vaccine regimen in 60 MD patients (six with a history of COVID-19).

Our results show that MD patients exhibit a high seroconversion rate (91.7%) but the anti-spike IgG antibodies (CMIA) tend to wane rapidly after full immunization. Only 51.7% of the patients developed T cell immune response. High anti-spike IgG antibodies may predict a better cellular immunity …